Jason Reddick at Work
A brief background summary of Combat Motors’ master builder and test-pilot, Jason Reddick.
After openly communicating my own vision and giving everyone an opportunity to contribute, there is no doubt that the team is fully invested into the growth and success of Combat Motors.” Ernest Lee
BIRMINGHAM, AL, USA, May 6, 2021 /EINPresswire.com/ There are few people in this world that can give you the distinct impression they could be left on a deserted island with nothing but a roll of duct tape and a clothespin; two days later you would get a selfie of him, with your favorite aunt, enjoying a couple of mojitos on the back of a yacht. halfway across the world. This is the first thought that comes to mind when we learn more about the history of Combat Motors’ master builder and test-pilot, Jason Reddick.
Intelligent.com Announces Best Online Construction Management Degree Programs for 2021
Share Article
Degree holders gain increased earning potential with career opportunities upon graduation from these top ranked online programs. SEATTLE (PRWEB) May 04, 2021 Intelligent.com, a trusted resource for online degree rankings and higher education planning, has announced the top online programs for 2021. The comprehensive research guide is based on an assessment of 1,280 accredited colleges and universities in the nation. Each program is evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment. The methodology also uses an algorithm which collects and analyzes multiple rankings into one score to easily compare each school.
E-Mail
There is currently no consensus on what quality end-of-life care for children with cancer looks like, or how to measure and deliver it; however, investigators recently assembled an expert panel to help fill this void. In a study published early online in
CANCER, a peer-reviewed journal of the American Cancer Society, the panel endorsed 16 measures that cover different aspects of care that are important for children with cancer and their families. Measuring the quality of the care delivered is an essential part of ensuring high quality end-of-life care for all patients. Although there are numerous quality measures for end-of-life care for adults with cancer, there are zero for children with cancer, said lead author Emily Johnston, MD, MS, of the University of Alabama at Birmingham.
From USA TODAY Network and wire reports
Alabama
Birmingham: Declaring the COVID-19 pandemic “absolutely” managed despite lagging vaccinations, Gov. Kay Ivey said Monday that she will end a health order meant to guard against the spread of an illness that has killed nearly 11,000 people statewide. Citing improved infection rates, fewer hospitalizations and more widespread immunizations, Ivey said the current order recommending that people follow health guidance and requiring some precautions for senior citizens and long-term care facilities will end May 31, barring a sharp rise in cases. The declared state of emergency will end July 6, she said in a statement. “For over a year now, Alabamians, like people around the globe, have made sacrifices and adjusted to a temporary ‘new normal.’ We have learned much since last year, and this is absolutely now a managed pandemic. Our infection rates and hospitalizations are in better shape, and over 1.5 million Alabamians have had at
May 5, 2021
Therapeutic drug monitoring, half-dosing may not be ready for prime-time
Therapeutic drug monitoring (TDM) for patients with immune-mediated inflammatory diseases did not lead to better clinical remission rates, while routine dose reduction of anti-rheumatic drugs for patients with rheumatoid arthritis (RA) in remission offered modest benefits, according to two Norwegian trials.
In the NOR-DRUM Part A trial, clinical remission at week 30 was achieved in 50.5% of 198 patients with TDM versus 53% of 200 patients in the standard therapy group, for an adjusted difference of 1.5% (95% CI −8.2% to 11.1%,
P=0.78), reported Silje Watterdal Syversen, MD, PhD, of Diakonhjemmet Hospital in Oslo, and co-authors.
In the ARCTIC REWIND trial, disease flare occurred in 25% of 77 patients in the half-dose conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) group versus 6% in the stable-dose csDMARD group for a risk difference of 18% (95% CI 7%-29%), reported Si